
JoAnn Pinkerton, MD, on Counseling Patients Starting Elinzanetant for VMS
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.
Elinzanetant produced rapid, progressively greater reductions in moderate-to-severe vasomotor symptoms (VMS), while its most frequently reported adverse events generally emerged early and were mild or moderate, according to 2 pooled analyses presented at The Menopause Society 2026 Annual Meeting in San Diego. In an interview, JoAnn V. Pinkerton, MD, MSCP, of University of Virginia Health, discussed how the findings can guide primary care counseling and follow-up.
The efficacy analysis included 410 US participants from the phase 3 OASIS-1 and OASIS-2 trials. Participants aged 40 to 65 years with at least 50 moderate-to-severe VMS episodes per week received elinzanetant 120 mg or placebo for 12 weeks, followed by elinzanetant for both groups through week 26. By week 12, 66.9% of elinzanetant-treated participants achieved at least a 50% reduction in VMS frequency, compared with 40.5% receiving placebo. Reductions of at least 75% and 90% were reported in 46.5% and 29.1% of the elinzanetant group, respectively. Pinkerton said patients may notice improvement within 1 week, with additional gains over time.
A separate pooled safety analysis evaluated 765 elinzanetant-treated participants and 754 placebo recipients through 12 weeks. Headache, fatigue, and somnolence occurred in 7.6%, 5.4%, and 3.4% of the elinzanetant group, respectively. Most first events occurred during the first 2 weeks. Nearly all were mild or moderate, with one severe headache reported. By 12 weeks after onset, 73.7% of first headache events, 43.9% of fatigue events, and 73.1% of somnolence events had resolved.
For PCPs, Pinkerton recommended setting expectations at treatment initiation: symptom relief may begin quickly and continue to build, while early fatigue, headache, or somnolence may diminish with time. This counseling may help patients distinguish expected, transient effects from symptoms requiring reassessment and support persistence when the initial response is slower than anticipated.
Patient Care Online: Across these 3 analyses of the OASIS 1 through 3 trials, what is the main message for clinicians who manage vasomotor symptoms?
JoAnn Pinkerton, MD: Elinzanetant is a dual neurokinin receptor inhibitor. It's an NK1 and NK3 receptor antagonist, and what we've shown in the global trials is that it worked for hot flash frequency and severity, improvement in sleep, and menopause-related quality of life.
We've already shown in OASIS 4 that it worked for vasomotor symptoms in women with breast cancer on endocrine therapy. Now, we want to look at subpopulations. We want to know whether it works as well as it did in the overall trials in women with late perimenopause, which is an understudied group, in women with natural or surgical menopause, and whether it works as well for women in the United States as it did globally.
Patient Care Online: Few nonhormonal treatments have been studied specifically in perimenopause. What did the late perimenopausal subgroup analysis show about elinzanetant's effects on VMS frequency and severity?
JoAnn Pinkerton, MD: This was a small post hoc group analysis of OASIS 1, 2, and 3, and what we wanted to know was whether it worked in women with late perimenopause.
We used the STRAW+10 criteria to determine whether women were actually in late perimenopause, and what we found was that it worked as well as it did in the overall populations for hot flash frequency and severity, improvements in sleep, and improvements in menopause-related quality of life.
Patient Care Online: How should clinicians interpret the perimenopausal findings given the small sample size of just 32 women and the absence of statistical testing?
JoAnn Pinkerton, MD: The small sample size limits the generalizability. It was only 32 women. However, they were in late perimenopause, and this is an understudied group.
The results were very encouraging because we found the same findings as in the global trials. It leads us to hope that if we conducted a randomized clinical trial in late perimenopause, we would find the same positive findings.
Patient Care Online: The sleep analysis found that the proportion of women reporting poor or very poor sleep quality declined from 65.6% to 20.5% with elinzanetant, compared with 57.8% to 38.7% with placebo. How should clinicians interpret this difference given the placebo response?
JoAnn Pinkerton, MD: First of all, sleep disruptions were very common in this population of women experiencing significant hot flashes. Second, there was a clinically meaningful difference in the improvement in sleep disturbances.
These women were not enrolled because of sleep disturbances; they were enrolled because of hot flashes. Seeing that difference leads us to think that women with significant sleep disturbances are going to show a clinically meaningful improvement in sleep.
The improvements were really in disturbed sleep, quality of sleep, and how refreshed they felt, which are all important for menopausal women.
Patient Care Online: In the US population analysis, 66.9% of women receiving elinzanetant achieved at least a 50% reduction in VMS frequency between weeks 4 and 12. How should clinicians use that responder threshold when counseling patients about treatment expectations?
JoAnn Pinkerton, MD: A 50% reduction in hot flashes is considered clinically meaningful, particularly because elinzanetant worked for severe hot flashes.
Clinicians can counsel their patients that they're going to see this 50% improvement by 4 weeks, with continued improvement at 12 weeks.
By 26 weeks, 75% of women had at least a 50% response, and about 30% had a 90% response, which is pretty dramatic and very similar to what we see with hormone therapy.
Patient Care Online: How should primary care physicians counsel patients about headache, fatigue, and somnolence when initiating elinzanetant?
JoAnn Pinkerton, MD: Providers need to discuss the most common side effects, which include fatigue, headache, and somnolence.
What's important is that these improved over time and did not lead to discontinuations in the clinical trial. They also conducted a driving test to make sure that driving was not impaired the next day, which it was not.
If women know that they might experience these side effects, they're going to be better able to tolerate them, realizing that they're going to improve over time and that they're going to experience substantial relief from hot flashes.
Patient Care Online: What should patients expect in terms of how quickly and how much their symptoms may improve with elinzanetant, and when should primary care physicians reassess whether treatment is working?
JoAnn Pinkerton, MD: Patients should expect very rapid improvements in their hot flashes within a week, but they're going to have continued improvements over time, at 4 weeks, 12 weeks, 26 weeks, and even 52 weeks.
I think the important clinical takeaway is that these products work, they improve over time, but they also work very rapidly.
Most nonhormonal treatments take 2 to 6 weeks to work. Women are going to find an improvement within a week, but then continued improvement.
If they're having a slow response, they need to be patient, and their providers need to be patient. The message is that symptoms can continue to get better over time, and if they have side effects, those are also expected to improve over time.
References:
- Simon JA, Nappi RE, Panay N, et al. Headache, fatigue, and somnolence as adverse events across elinzanetant’s clinical trials: a pooled safety analysis. Abstract S-3. Presented at: The Menopause Society 2026 Annual Meeting; San Diego, CA.
- Pinkerton JV, Tough DeSapri K, Clark A, et al. Proportion of postmenopausal participants achieving ≥50% reduction in moderate-to-severe vasomotor symptom frequency with elinzanetant: pooled US population data from OASIS-1 and OASIS-2. Abstract S-5. Presented at: The Menopause Society 2026 Annual Meeting; San Diego, CA.
Related to this article








